Intrinsic Molecular Subclassification of Urothelial Carcinoma of the Bladder: Are We Finally there?
Authors:
- Issam A. Al-BozomIAIssam A. Al-Bozom
- Mohamed Ben GashirMGMohamed Ben Gashir
- Noheir M. TahaNTNoheir M. Taha
- 1 July 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Advances in Anatomic Pathology
- Vol. 26 (4) , 251-256
Abstract
Bladder cancer is a highly prevalent disease throughout the world usually encountered in older patients, and associated with substantial morbidity, mortality, and cost. The treatment of bladder cancer has remained unchanged for the last several decades. However, in recent years the availability of comprehensive genomic data from The Cancer Genome Atlas and other large projects have considerably improved our understanding of the pathogenesis of these tumors. These studies demonstrated that bladder cancers can be grouped into 2 broad categories namely basal and luminal molecular subtypes with recognizable subgroups in each of these categories. Clinical data suggest that invasive basal cancers are more sensitive to neoadjuvant chemotherapy (NAC), such that most patients with basal cancers who are aggressively managed with NAC have excellent outcomes. Patients with luminal cancers do not appear to derive much clinical benefit from NAC, but some may appear to be sensitive to anti-programmed death-ligand 1 (PDL1) antibodies and possibly other immune checkpoint inhibitors. It is hoped that future studies will also identify biomarkers such as immunohistochemical markers which may be used to predict therapeutic response of these tumors. This will contribute substantially toward efficient and cost-effective diagnosis and management of these neoplasms.Keywords
This publication has 38 references indexed in Scilit:
- Molecular Pathology of Breast CancerAmerican Journal of Clinical Pathology, 2012
- The bladder cancer genome; chromosomal changes as prognostic makers, opportunities, and obstaclesUrologic Oncology: Seminars and Original Investigations, 2012
- Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial CarcinomaPLOS ONE, 2012
- Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progressionUrologic Oncology: Seminars and Original Investigations, 2010
- Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and OutcomeCancer Research, 2010
- The present and future burden of urinary bladder cancer in the worldWorld Journal of Urology, 2009
- Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategyLaboratory Investigation, 2008
- Urothelial tumorigenesis: a tale of divergent pathwaysNature Reviews Cancer, 2005
- Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiformeProceedings of the National Academy of Sciences, 2005
- Mapping Cancerous and Precancerous Bladder ChangesJAMA, 1974